An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study).

Publication Type:

Journal Article


The Journal of infectious diseases, Volume 203, Issue 6, p.765-72 (2011)


2011, Adenoviruses, Human, Adult, AIDS Vaccines, Anti-Retroviral Agents, Blotting, Western, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, Circumcision, Male, Clinical Research Division, Disease-Free Survival, Double-Blind Method, Genetic Vectors, HIV Infections, HIV-1, Humans, Immunity, Cellular, Male, Middle Aged, Placebos, Proportional Hazards Models, Public Health Sciences Division, RNA, Viral, Vaccine and Infectious Disease Division, Viral Load, Young Adult


The Step study was a randomized trial to determine whether an adenovirus type 5 (Ad5) vector vaccine, which elicits T cell immunity, can lead to control of human immunodeficiency virus (HIV) replication in participants who became HIV-infected after vaccination.